Clinical Trial Update: A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial ADAGIO-2 is evaluating the safety and efficacy of KarXT plus KarX-EC for agitation in Alzheimer's disease and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• KarX-EC
• KarXT (xanomeline-trospium)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Alzheimer Disease | Phase 3 | Status: RECRUITING